Literature DB >> 17081976

The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly.

Vladimir Joukov1, Aaron C Groen, Tatyana Prokhorova, Ruth Gerson, Erinn White, Alison Rodriguez, Johannes C Walter, David M Livingston.   

Abstract

The heterodimeric tumor-suppressor complex BRCA1/BARD1 exhibits E3 ubiquitin ligase activity and participates in cell proliferation and chromosome stability control by incompletely defined mechanisms. Here we show that, in both mammalian cells and Xenopus egg extracts, BRCA1/BARD1 is required for mitotic spindle-pole assembly and for accumulation of TPX2, a major spindle organizer and Ran target, on spindle poles. This function is centrosome independent, operates downstream of Ran GTPase, and depends upon BRCA1/BARD1 E3 ubiquitin ligase activity. Xenopus BRCA1/BARD1 forms endogenous complexes with three spindle-pole proteins, TPX2, NuMA, and XRHAMM--a known TPX2 partner--and specifically attenuates XRHAMM function. These observations reveal a previously unrecognized function of BRCA1/BARD1 in mitotic spindle assembly that likely contributes to its role in chromosome stability control and tumor suppression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17081976     DOI: 10.1016/j.cell.2006.08.053

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  131 in total

1.  The kinetochore protein Bub1 participates in the DNA damage response.

Authors:  Chunying Yang; Haibo Wang; Yiran Xu; Kathryn L Brinkman; Hiromichi Ishiyama; Stephen T C Wong; Bo Xu
Journal:  DNA Repair (Amst)       Date:  2011-11-09

2.  BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.

Authors:  Reena Shakya; Latarsha J Reid; Colleen R Reczek; Francesca Cole; Dieter Egli; Chyuan-Sheng Lin; Dirk G deRooij; Steffen Hirsch; Kandasamy Ravi; James B Hicks; Matthias Szabolcs; Maria Jasin; Richard Baer; Thomas Ludwig
Journal:  Science       Date:  2011-10-28       Impact factor: 47.728

3.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

Authors:  Da Yang; Sofia Khan; Yan Sun; Kenneth Hess; Ilya Shmulevich; Anil K Sood; Wei Zhang
Journal:  JAMA       Date:  2011-10-12       Impact factor: 56.272

4.  A mitotic role for the DNA damage-responsive CHK2 kinase.

Authors:  Ko Sato; Tomohiko Ohta; Ashok R Venkitaraman
Journal:  Nat Cell Biol       Date:  2010-05       Impact factor: 28.824

5.  Tumor suppressor NF2/Merlin is a microtubule stabilizer.

Authors:  Zlatko Smole; Claudio R Thoma; Kathryn T Applegate; Maria Duda; Katrin L Gutbrodt; Gaudenz Danuser; Wilhelm Krek
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

Review 6.  TPX2: of spindle assembly, DNA damage response, and cancer.

Authors:  Gernot Neumayer; Camille Belzil; Oliver J Gruss; Minh Dang Nguyen
Journal:  Cell Mol Life Sci       Date:  2014-02-21       Impact factor: 9.261

7.  ATM controls proper mitotic spindle structure.

Authors:  Luca Palazzo; Rosa Della Monica; Roberta Visconti; Vincenzo Costanzo; Domenico Grieco
Journal:  Cell Cycle       Date:  2014-02-06       Impact factor: 4.534

8.  BRCA1 and FancJ cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1.

Authors:  Jianqiu Zou; Deli Zhang; Guang Qin; Xiangming Chen; Hongmin Wang; Dong Zhang
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Changes in estrogen receptor-alpha variant (ER-alpha36) expression during mouse ovary development and oocyte meiotic maturation.

Authors:  Bao-Zeng Xu; Sheng-Li Lin; Mo Li; Jia-Qiao Zhu; Sen Li; Ying-Chun Ouyang; Da-Yuan Chen; Qing-Yuan Sun
Journal:  Histochem Cell Biol       Date:  2008-10-28       Impact factor: 4.304

Review 10.  The multiple layers of ubiquitin-dependent cell cycle control.

Authors:  Katherine Wickliffe; Adam Williamson; Lingyan Jin; Michael Rape
Journal:  Chem Rev       Date:  2009-04       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.